These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18181713)

  • 1. Environmental assessment requirements for live biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S112-4; discussion S144-51. PubMed ID: 18181713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Product development of probiotics as biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of probiotics as biologic drugs.
    Hoffman FA
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S125-7; discussion S144-51. PubMed ID: 18181717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification.
    Mattia A; Merker R
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S115-8; discussion S144-51. PubMed ID: 18181714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergen-free probiotics.
    Mogna G; Strozzi GP; Mogna L
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S201-4. PubMed ID: 18685500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Business considerations in the development of probiotics.
    Hoffman FA
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S141-3; discussion S144-51. PubMed ID: 18181721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 10. Food and Drug Administration regulations and licensure.
    Barker LF
    Fed Proc; 1975 May; 34(6):1522-4. PubMed ID: 1126452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations in the development of live biotherapeutic products for clinical use.
    Ross JJ; Boucher PE; Bhattacharyya SP; Kopecko DJ; Sutkowski EM; Rohan PJ; Chandler DK; Vaillancourt J
    Curr Issues Mol Biol; 2008; 10(1-2):13-6. PubMed ID: 18525102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probiotics: definition, sources, selection, and uses.
    Sanders ME
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S58-61; discussion S144-51. PubMed ID: 18181724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current marketplace for probiotics: a Japanese perspective.
    Amagase H
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S73-5; discussion S144-51. PubMed ID: 18181727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 15. Health-benefit claims for probiotic products.
    Heimbach JT
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S122-4; discussion S144-51. PubMed ID: 18181716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The US Food and Drug Administration and probiotics: regulatory categorization.
    Degnan FH
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of final container residual moisture in freeze-dried biological products.
    May JC; Wheeler RM; Etz N; Del Grosso A
    Dev Biol Stand; 1992; 74():153-64. PubMed ID: 1592165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs.
    Hoffman FA; Heimbach JT; Sanders ME; Hibberd PL
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S53-7. PubMed ID: 18181723
    [No Abstract]   [Full Text] [Related]  

  • 20. Biological products regulated under Section 351 of the Public Health Service Act; implementation of biologics license; elimination of establishment license and product license; public workshop--FDA. Proposed rule; notice of workshop.
    Fed Regist; 1998 Aug; 63(154):42773-4. PubMed ID: 10182565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.